AU2025230731A1 — Controlled-release CNP agonists with reduced side-effects
Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2025-10-02 · 1y expired
What this patent protects
The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled release CNP agonist and to methods of treatment. This data, for application number 2022224732, is c…
USPTO Abstract
The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled release CNP agonist and to methods of treatment. This data, for application number 2022224732, is current as of 2025-09-11 12:06 AEST
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.